Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment
Daniel Victor Ortigoza, Vice Chair of the Argentine Federation of Cardiology’s Cardio-Oncology Committee, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine, adding:
“Bleeding Risk with Apixaban versus Rivaroxaban in Acute Venous Thromboembolism.
Patients with acute symptoms of pulmonary embolism or proximal deep vein thrombosis who were to receive apixaban or rivaroxaban for 3 months were included.
Apixaban was administered at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily, and rivaroxaban at a dose of 15 mg twice daily for 21 days, followed by 20 mg daily.
The primary outcome measure was clinically relevant bleeding (CRB)-a composite of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) according to the definitions of the International Society on Thrombosis and Haemostasis (ISTH).
A primary event occurred in 44 of 1,345 patients (3.3 percent) in the apixaban group and in 96 of 1,355 (7.1 percent) in the rivaroxaban group (relative risk: 0.46; 95 percent confidence interval [CI]: 0.33 to 0.65; P less than 0.001)
Central figure: Clinically Relevant Bleeding.
Shown are Kaplan–Meier curves for the first episode of clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, during the 3-month treatment period (primary outcome).
The inset shows the same data on an enlarged y-axis.
Shading indicates 95 percent confidence intervals.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 27, 2026, 23:04Stefano Navarro: Hypertension Reprogrammes Megakaryocytes and Increases Platelet Responsiveness to Thrombin
-
Oct 27, 2026, 23:03Enrique M. San Norberto García: What Is the Best Treatment for Femoropopliteal in-Stent Restenosis
-
Oct 27, 2026, 23:01Mandy-Lyn Crispim: One Donation Can Help Save More Than One Life
-
Oct 27, 2026, 23:00Teresa Buzzoni: AABB 2026 Through the Eyes of a Newcomer to the Blood Industry
-
Oct 27, 2026, 22:59Josephine Cantu: The Incredible Science Behind Blood Clotting – A Life-Saving Process
-
Oct 27, 2026, 22:56Edward Lee Carter: First Factor XIa Inhibitor Approved Worldwide – U.S. FDA Decision Expected in November
-
Oct 27, 2026, 22:56Anne Troldborg: Preventing Thrombosis in SLE Before the First Event
-
Oct 27, 2026, 22:53Shadi Tabibian: Tazehnameh November 2026 Covers Key Developments in Hemophilia Care
-
Oct 27, 2026, 22:52Danny Hsu: THANZ Makes History With Its First Dedicated HHT Symposium at Blood 2026